Currently, there are 41.79M common shares owned by the public and among those 21.12M shares have been available to trade.
The company’s stock has a 5-day price change of -0.16% and 8.99% over the past three months. CARM shares are trading -56.22% year to date (YTD), with the 12-month market performance up to 7.66% higher. It has a 12-month low price of $0.14 and touched a high of $1.90 over the same period. CARM has an average intraday trading volume of 13.71 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 26.87%, 71.41%, and -20.01% respectively.
Institutional ownership of Carisma Therapeutics Inc (NASDAQ: CARM) shares accounts for 8.10% of the company’s 41.79M shares outstanding.
It has a market capitalization of $18.84M and a beta (3y monthly) value of 1.67. The earnings-per-share (ttm) stands at -$1.22. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.17% over the week and 39.63% over the month.
Analysts forecast that Carisma Therapeutics Inc (CARM) will achieve an EPS of -0.09 for the current quarter, -0.1 for the next quarter and -0.66 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.09 while analysts give the company a high EPS estimate of -0.09. Comparatively, EPS for the current quarter was -0.27 a year ago. Earnings per share for the fiscal year are expected to increase by 50.00%, and -2.33% over the next financial year. EPS should shrink at an annualized rate of 24.74% over the next five years, compared to 42.71% over the past 5-year period.
Looking at the support for the CARM, a number of firms have released research notes about the stock. Robert W. Baird stated their Neutral rating for the stock in a research note on December 12, 2024, with the firm’s price target at $10-$1. BTIG Research was of a view on April 11, 2024 that the stock is Buy, while CapitalOne gave the stock Overweight rating on October 03, 2023, issuing a price target of $10. Evercore ISI on their part issued Outperform rating on July 06, 2023.
